Search Results for: results

Estimating treatment effects for individual patients based on the results of randomised clinical trials


BMJ 2011; 343:d5888 doi: 10.1136/bmj.d5888 (Published 3 October 2011) Cite this as: BMJ 2011; 343:d5888 Research Estimating treatment effects for individual patients based on the results of randomised clinical trials OPEN ACCESS Johannes A N Dorresteijn, epidemiologist and medical doctor1, Frank L J Visseren, professor of vascular medicine, epidemiologist, and internist1,  Paul M Ridker, Eugene Braunwald professor of medicine, epidemiologist, and cardiologist2,  … Continue reading Estimating treatment effects for individual patients based on the results of randomised clinical trials

Statement from the American Heart Association on ENHANCE Study Results


DALLAS, TX — January 16, 2008 — Merck/Schering-Plough Pharmaceuticals released results from the ENHANCE trial, which found that the ezetimibe/simvastatin (Zetia/Zocor) combination drug known as Vytorin was no more effective in reducing artery plaque build-up than simvastatin (Zocor) alone. There were no statistically significant differences in the safety of the drugs, which are used to … Continue reading Statement from the American Heart Association on ENHANCE Study Results

ENHANCE Results Yield Disappointment for Ezetimibe


ENHANCE Results Yield Disappointment for Ezetimibe from Heartwire — a professional news service of WebMD Sue Hughes   January 14, 2008 (Whitehouse Station/Kenilworth NJ) – The results of the long-awaited and controversial ENHANCE trial, finally announced today, have shown no benefit of the combination of ezetimibe (Zetia, Merck/Schering-Plough Pharmaceuticals) and simvastatin (sold together as Vytorin, … Continue reading ENHANCE Results Yield Disappointment for Ezetimibe

Estudio SMART: salmeterol y asma A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the SMART Study Group * From the National Jewish Medical and Research Center (Dr. Nelson), Denver, CO; Brigham and Women’s Hospital and Harvard Medical School (Dr. Weiss), Boston, MA; Wake Forest University School of Medicine (Dr. Bleecker), Winston Salem, NC; and GlaxoSmithKline (Mr. Yancey and Dr. Dorinsky), Research Triangle Park, NC.More… Correspondence to: Paul M. Dorinsky, MD, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709; e-mail: paul.m.dorinsky@gsk.com Abstract Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care. Design: A 28-week, randomized, double-blind, placebo-controlled, observational study. Setting: Study subjects were seen once in the study physician’s office for screening and were provided all blinded study medication for the entire study period. Follow-up by telephone was scheduled every 4 weeks. Participants: Subjects (> 12 years old) with asthma as judged by the study physician were eligible. Individuals with a history of long-acting ß2-agonist use were excluded. Interventions: Salmeterol, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI. Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated due to findings in African Americans and difficulties in enrollment. The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for salmeterol vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14). There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo. The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo. Conclusions: For the primary end point in the total population, there were no significant differences between treatments. There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol. Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects. Whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown. Estudio SMART: The Salmeterol Multicenter Asthma Research Trial


The Salmeterol Multicenter Asthma Research Trial A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the SMART Study Group * From the National Jewish Medical and Research Center (Dr. Nelson), Denver, … Continue reading Estudio SMART: salmeterol y asma

A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol

Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the SMART Study Group

* From the National Jewish Medical and Research Center (Dr. Nelson), Denver, CO; Brigham and Women’s Hospital and Harvard Medical School (Dr. Weiss), Boston, MA; Wake Forest University School of Medicine (Dr. Bleecker), Winston Salem, NC; and GlaxoSmithKline (Mr. Yancey and Dr. Dorinsky), Research Triangle Park, NC.More…

Correspondence to: Paul M. Dorinsky, MD, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709; e-mail: paul.m.dorinsky@gsk.com

Abstract

Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care.

Design: A 28-week, randomized, double-blind, placebo-controlled, observational study.

Setting: Study subjects were seen once in the study physician’s office for screening and were provided all blinded study medication for the entire study period. Follow-up by telephone was scheduled every 4 weeks.

Participants: Subjects (> 12 years old) with asthma as judged by the study physician were eligible. Individuals with a history of long-acting ß2-agonist use were excluded.

Interventions: Salmeterol, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI.

Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated due to findings in African Americans and difficulties in enrollment. The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for salmeterol vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14). There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo. The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo.

Conclusions: For the primary end point in the total population, there were no significant differences between treatments. There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol. Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects. Whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown.
Estudio SMART: The Salmeterol Multicenter Asthma Research Trial

Estudio SMART: salmeterol y asma A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the SMART Study Group * From the National Jewish Medical and Research Center (Dr. Nelson), Denver, CO; Brigham and Women’s Hospital and Harvard Medical School (Dr. Weiss), Boston, MA; Wake Forest University School of Medicine (Dr. Bleecker), Winston Salem, NC; and GlaxoSmithKline (Mr. Yancey and Dr. Dorinsky), Research Triangle Park, NC.More… Correspondence to: Paul M. Dorinsky, MD, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709; e-mail: paul.m.dorinsky@gsk.com Abstract Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care. Design: A 28-week, randomized, double-blind, placebo-controlled, observational study. Setting: Study subjects were seen once in the study physician’s office for screening and were provided all blinded study medication for the entire study period. Follow-up by telephone was scheduled every 4 weeks. Participants: Subjects (> 12 years old) with asthma as judged by the study physician were eligible. Individuals with a history of long-acting ß2-agonist use were excluded. Interventions: Salmeterol, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI. Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated due to findings in African Americans and difficulties in enrollment. The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for salmeterol vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14). There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo. The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo. Conclusions: For the primary end point in the total population, there were no significant differences between treatments. There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol. Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects. Whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown. Estudio SMART: The Salmeterol Multicenter Asthma Research Trial


The Salmeterol Multicenter Asthma Research Trial A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the SMART Study Group * From the National Jewish Medical and Research Center (Dr. Nelson), Denver, … Continue reading Estudio SMART: salmeterol y asma

A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol

Harold S. Nelson, MD; Scott T. Weiss, MD, MS; Eugene R. Bleecker, MD; Steven W. Yancey, MS; Paul M. Dorinsky, MD; the SMART Study Group

* From the National Jewish Medical and Research Center (Dr. Nelson), Denver, CO; Brigham and Women’s Hospital and Harvard Medical School (Dr. Weiss), Boston, MA; Wake Forest University School of Medicine (Dr. Bleecker), Winston Salem, NC; and GlaxoSmithKline (Mr. Yancey and Dr. Dorinsky), Research Triangle Park, NC.More…

Correspondence to: Paul M. Dorinsky, MD, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709; e-mail: paul.m.dorinsky@gsk.com

Abstract

Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care.

Design: A 28-week, randomized, double-blind, placebo-controlled, observational study.

Setting: Study subjects were seen once in the study physician’s office for screening and were provided all blinded study medication for the entire study period. Follow-up by telephone was scheduled every 4 weeks.

Participants: Subjects (> 12 years old) with asthma as judged by the study physician were eligible. Individuals with a history of long-acting ß2-agonist use were excluded.

Interventions: Salmeterol, 42 µg bid via metered-dose inhaler (MDI), and placebo bid via MDI.

Measurements and results: Following an interim analysis in 26,355 subjects, the study was terminated due to findings in African Americans and difficulties in enrollment. The occurrence of the primary outcome, respiratory-related deaths, or life-threatening experiences was low and not significantly different for salmeterol vs placebo (50 vs 36; relative risk [RR] = 1.40; 95% confidence interval [CI], 0.91 to 2.14). There was a small, significant increase in respiratory-related deaths (24 vs 11; RR, 2.16; 95% CI, 1.06 to 4.41) and asthma-related deaths (13 vs 3; RR, 4.37; 95% CI, 1.25 to 15.34), and in combined asthma-related deaths or life-threatening experiences (37 vs 22; RR, 1.71; 95% CI, 1.01 to 2.89) in subjects receiving salmeterol vs placebo. The imbalance occurred largely in the African-American subpopulation: respiratory-related deaths or life-threatening experiences (20 vs 5; RR, 4.10; 95% CI, 1.54 to 10.90) and combined asthma-related deaths or life-threatening experiences (19 vs 4; RR, 4.92; 95% CI, 1.68 to 14.45) in subjects receiving salmeterol vs placebo.

Conclusions: For the primary end point in the total population, there were no significant differences between treatments. There were small, but statistically significant increases in respiratory-related and asthma-related deaths and combined asthma-related deaths or life-threatening experiences in the total population receiving salmeterol. Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects. Whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown.
Estudio SMART: The Salmeterol Multicenter Asthma Research Trial

In Cancer Screening, Why Not Tell the Truth?


John M Mandrola, MD |January 12, 2016 An unpleasant emotion caused by the belief that something is dangerous. This is fear. This is cancer. The motivation to screen for cancer, therefore, is easy to understand. The problem: cancer screening has not worked. Recent reviews of the evidence show that current-day screening techniques do not save lives. Worse, … Continue reading In Cancer Screening, Why Not Tell the Truth?

Recursos en Medicina Basada en la Evidencia


Evidence Updates: from McMaster University. Short comments from Cochrane Collaboration. Epistemonikus: mix the best medical evidence and information technologies for clinical decisitions or public health policies. In spanish.  Evidence in Medicine Cochrane Library:  Health Technology Assesment Database from Cochrane Collaboration. Essential Evidence Plus:  is the only evidence-based, point-of-care clinical decision support system that gives you access … Continue reading Recursos en Medicina Basada en la Evidencia

EASL 2015: ¿Es posible erradicar la hepatitis C en el mundo?


Fuente: gTt-VIH Un simposio celebrado durante el congreso centró su atención en las posibilidades de erradicar la infección y las barreras que habría que superar para ello Miguel Vázquez – 06/05/2015 Los nuevos fármacos de acción directa (DAA) para tratar la hepatitis C tienen una elevada eficacia y son mucho más tolerables que las opciones … Continue reading EASL 2015: ¿Es posible erradicar la hepatitis C en el mundo?

La hepatitis C y la crisis en España por la falta de acceso público a nuevos medicamentos


Un poco confuso este video, dónde en principio se cuestionan varios aspectos de la fisiopatologia de la enfermedad, la prevalencia del problema, la efectividad de los medicamentos, los métodos diagnósticos, para luego reclamar por el coste de los mismos, y su acceso universal. Pero sin dudas pone de relieve, el problema al que se está … Continue reading La hepatitis C y la crisis en España por la falta de acceso público a nuevos medicamentos

Nonpharmacologic Treatment of Functional Abdominal Pain Disorders: A Systematic Review. Pediatrics


BACKGROUND AND OBJECTIVE: Various nonpharmacologic treatments are available for pediatric abdominal pain-related functional gastrointestinal disorders (AP–FGIDs). Data on efficacy and safety are scarce. The goal of this study was to summarize the evidence regarding nonpharmacologic interventions for pediatric AP-FGIDs: lifestyle interventions, dietary interventions, behavioral interventions, prebiotics and probiotics, and alternative medicine. METHODS: Searches were conducted … Continue reading Nonpharmacologic Treatment of Functional Abdominal Pain Disorders: A Systematic Review. Pediatrics

Efectividad de la paroxetina en la depresión mayor en adultos


Barbui C,, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 2008; 178: 296-305.  R   TC   PDF Introducción Los inhibidores selectivos de la recaptación de la serotonina (ISRS) son los fármacos más utilizados en … Continue reading Efectividad de la paroxetina en la depresión mayor en adultos

Most discontinued trials remain unpublished


Source: All Trials   A new research paper in JAMA looking at 1017 clinical trials has found that most trials stopped before the planned end remain unpublished, and overall 56% never published results. An international research group was given access to the records of all the clinical trials approved by six ethics committees in Switzerland, … Continue reading Most discontinued trials remain unpublished

Tools for learning


Algunas de las mejores y menos utilizadas herramientas disponibles en internet. Easy-to-use and secure Internet browser?Firefox, Chrome e-Mail system? Gmail Social bookmarking tool? del.icio.us Social bookmarking tool with collaborative learning features (groups, forums, etc.)? Diigo Social curation community? Pearltrees Tool that enables me to capture, visualize, organize and share my bookmarks? SimplyBox Tool to easily capture information in any environment … Continue reading Tools for learning

Drugs and business in psyquiatry


Los medicamentos psiquiátricos son drogas adictivas de alto poder y su administración sólo encubre oscuros intereses económicos. Los psiquiatras, por otra parte, siempre en pos de aumentar su riqueza, inventan enfermedades a las que les ponen nombres que no tienen nada que ver con el origen del trastorno. Ni siquiera se puede decir a favor … Continue reading Drugs and business in psyquiatry

Yazmin ( drosperinone and estradiol ) adverse reactions


Birth control pill (Photo credit: Wikipedia) For the Consumer Applies to drospirenone / ethinyl estradiol: oral tablet Get emergency medical help if you have any of these signs of an allergic reaction while taking drospirenone / ethinyl estradiol: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Stop using birth control pills and call … Continue reading Yazmin ( drosperinone and estradiol ) adverse reactions

Safety Patients: Olmesartan


Olmesartan: Drug Safety Communication – FDA Review Finds Cardiovascular Risks for Diabetics Not Conclusive Includes: Benicar, Benicar HCT, Azor, Tribenzor, and Generics AUDIENCE: Cardiology, Pharmacy, Family Practice, Endocrinology ISSUE: FDA has completed its safety review and has found no clear evidence of increased cardiovascular risks associated with use of the blood pressure medication olmesartan in … Continue reading Safety Patients: Olmesartan

Radical Prostatectomy or Radiotherapy in High-Risk Prostate Cancer


Clin Genitourin Cancer. 2014 Feb 6. pii: S1558-7673(14)00018-4. doi: 10.1016/j.clgc.2014.01.010. [Epub ahead of print] Radical Prostatectomy or Radiotherapy in High-Risk Prostate Cancer: A Systematic Review and Metaanalysis. Petrelli F1, Vavassori I2, Coinu A3, Borgonovo K3, Sarti E4, Barni S3. Author information 1Oncology Department, Medical Oncology Unit, Azienda Ospedaliera Treviglio, Treviglio, Bergamo, Italy. Electronic address: faupe@libero.it. … Continue reading Radical Prostatectomy or Radiotherapy in High-Risk Prostate Cancer

New Criteria May Change Alzheimer’s Diagnosis


Recently revised guidelines for diagnosing Alzheimer’s disease would reclassify nearly all patients who are currently diagnosed with mild or very mild Alzheimer’s as having mild cognitive impairment (MCI), a new study finds. The change may be confusing for doctors and misleading for patients and their families, says Dr. John Morris, a neurologist at Washington University in St. … Continue reading New Criteria May Change Alzheimer’s Diagnosis

Difference in clinical trials according to funding source


Image via Wikipedia Difference in clinical trials according to funding source An interesting article appears  in JAMA, and shows how the source funding of clinical trials on cardiovascular differs between those entities that are funded by non-profit from those so. It took all editions published by JAMA, The Lancet and the NEJM between 2000 and 2005, and analyzed … Continue reading Difference in clinical trials according to funding source

La prescripcion de THS en EEUU disminuyo rapidamente despues de la publicacion de trabajos que cuestionaban su eficacia


Image via Wikipedia La prescripcion de THS en EEUU disminuyo rapidamente despues de la publicacion de trabajos que cuestionaban su eficacia Hersh AL, Stefanick ML, Stafford RS. National Use of Postmenopausal Hormone Therapy. JAMA 2004; 291: 47-53.  R TC (s) PDF (s) Introducción La prescripción de tratamiento hormonal sustitutivo (THS) ha aumentado de forma importante en las … Continue reading La prescripcion de THS en EEUU disminuyo rapidamente despues de la publicacion de trabajos que cuestionaban su eficacia

Pharmalot: A Paroxetine study and retractation


 Pharma Blog » 2012 » February » 06 Brown University, A Paxil Study And Retractions By Ed Silverman // February 6th, 2012  For the past few years, an effort has been under way by a pair of academics to retract a study about the Paxil antidepressant in the Journal of the American Academy of Child and Adolescent Psychiatry that concluded the GlaxoSmithKline pill was … Continue reading Pharmalot: A Paroxetine study and retractation

Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks’ gestation.


AVC en Pediatria Basada en la Evidencia: González de Dios J, Molina Arias M. Resultados de los corticoides prenatales en el límite de la viabilidad. Evid Pediatr. 2012;8:12. JAMA. 2011 Dec 7;306(21):2348-58. Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks’ gestation. Carlo WA, McDonald SA, Fanaroff AA, Vohr BR, Stoll BJ, Ehrenkranz RA, Andrews … Continue reading Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks’ gestation.

Investigacion y ciencia en America Latina


Image via Wikipedia Via: Salud Loreto Investigar en America Latina, parece ser uno de los mayores problemas existentes. Pese a que Argentina ha repatriado investigadores, muchos de ellos no cobran en tiempo y forma. Nuestro desarrollo tecnologico se basa en leyes, como la ley del software, defienden el copyright, y nuestros programadores se han transformados … Continue reading Investigacion y ciencia en America Latina

In Atheists We Distrust


Image via Wikipedia In Atheists We DistrustSubjects believe that people behave better when they think that God is watching over them By Daisy Grewal  | January 17, 2012 | 124   Pherhaps this is the reason why most of people believe in a dollar than other things: “in God we Trust”…….. For jobs that require a … Continue reading In Atheists We Distrust

Risk factors and interventions with statistically significant tiny effects


Risk factors and interventions with statistically significant tiny effectsGeorge CM Siontis1 and John PA Ioannidis1,2,*+ Author Affiliations1Clinical Trials and Evidence-Based Medicine Unit and the Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece and 2Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, … Continue reading Risk factors and interventions with statistically significant tiny effects

Estatinas para niños


Image via WikipediaFuente: Enrique GavilanVia: Lista MEDFAM-APS EspañaEl JAMA acaba de publicar un artículo de análisis, que adjunto,intentando discutir las consecuencias que puede tener el recienteinforme de expertos norteamericanos sobre detección precoz dehipercolesterolemia en niños y adolescentes (éste:http://www.nhlbi.nih.gov/guidelines/cvd_ped/summary.htm#chap9).Sólo se salvan los bebés; a partir de los 2 añitos el sólo hecho deque tengas un padre … Continue reading Estatinas para niños

More abut Tamiflu


Image via Wikipedia By Michael Smith, North American Correspondent, MedPage TodayPublished: January 17, 2012Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco. A new review of the influenza drug oseltamivir (Tamiflu) has raised questions about both the efficacy of the medication and the commitment of its maker to supply enough data for … Continue reading More abut Tamiflu

Effect of Aspirin on Vascular and Nonvascular Outcomes Meta-analysis of Randomized Controlled Trials


Image via WikipediaEffect of Aspirin on Vascular and Nonvascular Outcomes Meta-analysis of Randomized Controlled Trials Sreenivasa Rao Kondapally Seshasai, MD, MPhil; Shanelle Wijesuriya, MA, MBBChir; Rupa Sivakumaran, MA, MBBChir; Sarah Nethercott, MA, MBBChir;Sebhat Erqou, MD, PhD; Naveed Sattar, MD, PhD; Kausik K. Ray, MD  Arch Intern Med. Published online January 9, 2012. doi:10.1001/archinternmed.2011.628 Background  The net benefit of aspirin in prevention of … Continue reading Effect of Aspirin on Vascular and Nonvascular Outcomes Meta-analysis of Randomized Controlled Trials

Roche Refuses To Disclose Tamiflu Data: Scientists


Roche Refuses To Disclose Tamiflu Data: Scientists An influential review that is due out tomorrow will not contain up-to-date efficacy information about Tamiflu, the widely used influenza drug sold by Roche, because researchers at the Cochrane Collaboration say they were stymied by the drugmaker in their efforts to fully assess the medication, according to reports. … Continue reading Roche Refuses To Disclose Tamiflu Data: Scientists

Pelvic Examination


Pelvic Examination A pelvic examination is a complete physical exam of a woman’s pelvic organs  by a health professional. A pelvic exam helps a health professional evaluate the size and position of the vagina,cervix, uterus, and ovaries. It is an important part of preventive health care for all adult women. A pelvic exam is done to help detect certain … Continue reading Pelvic Examination